Danaher (NYSE: DHR) Breaks Out on a HUGE Earnings Beat — Could Rise 28%

Danaher Corporation (NYSE: DHR) just broke out of a nine-month symmetrical triangle on a powerful +4.29% post-earnings surge — and looks headed even higher.

As we’ll get to just ahead, the combination of a better-than-expected earnings report with a raised full-year outlook, a new AI partnership with one of the biggest names in tech, and a fresh technical breakout makes DHR one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Danaher is a Washington, D.C.-based science and technology conglomerate that designs and manufactures biomanufacturing equipment and supplies, research instruments, and clinical diagnostic systems through three segments — Biotechnology, Life Sciences, and Diagnostics. Its portfolio includes well-known brands such as Cytiva, Beckman Coulter, Leica Microsystems, SCIEX, Integrated DNA Technologies, Abcam, and — since June 2026 — patient-monitoring specialist Masimo.

In plain English, when a drugmaker needs to grow and purify a new biologic medicine, when a research lab needs to analyze DNA or proteins, or when a hospital needs to run a test to diagnose a patient, there’s a good chance Danaher’s equipment — and, just as importantly, the disposable supplies that keep that equipment running — is involved. Its business hinges on biopharma manufacturing demand, research and academic budgets, hospital testing volumes, and how quickly it can layer AI and automation onto its massive installed base of lab instruments.

DHR’s latest move reflects a powerful confluence of developments — financial, strategic, and technological — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and DHR is looking less like a post-pandemic laggard stuck in a long downtrend and more like a cash-rich life-sciences leader with re-accelerating core growth, a freshly raised earnings outlook, an expanded diagnostics franchise, and a credible AI push with one of the most influential companies in tech.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Symmetrical Triangle Pattern Breakout: DHR has spent the better part of nine months coiling inside a large symmetrical triangle, marked in purple on the daily chart. The upper rail descends from the January high near $243, and the lower rail rises from the May low near $160. Each rally stalled at a lower high and each dip found buyers at a higher low, which is the classic signature of volatility compression as buyers and sellers converge on a decision point. Yesterday’s session delivered that decision emphatically. The stock opened at $217.55, right on the triangle’s lower rail, and rallied +4.29% to close at $233.86 — near the session high and clean above the upper boundary — on 8.9M shares, one of the heaviest volume prints since the July spike. The path matters as much as the destination: a first push above the upper rail in mid-October faded, price dropped back to test the lower rail, and buyers then drove it through the full width of the pattern in a single session. That sequence reads as a shakeout followed by absorption of overhead supply, not a drift higher on thin conviction. The remaining hurdle is the $237 horizontal level, where supply capped the stock in January, and clearing it is the confirmation trigger for the breakout entry.

DHR – Daily Chart

#2 Price Above 50-MA and 200-MA: DHR now trades above both its 50-day SMA ($215.12) and 200-day SMA ($201.26), with the 50-day stacked above the 200-day in golden-cross alignment. That cross formed in mid-September near $202. The two averages are also moving differently in a way that helps the setup. The 50-day is rising steadily, while the 200-day has flattened after declining through the spring, so the long-term average is shifting from headwind to floor. The support structure is tiered and well defined. The first line of defense is the 50-day near $215, which is converging with the triangle’s lower rail near $217, and that overlap gives the level unusual weight. The 200-day near $201 is the deeper structural backstop. One caveat worth stating plainly — price sits roughly 9% above the 50-day after yesterday’s surge, so the stock is extended in the near term. A pullback toward $230, where the old upper rail sits, would be a healthy retest of the breakout rather than a crack in the thesis, and that is exactly why the setup offers a second entry there.

#3 Bullish ADX and DI: The directional read is decisive. +DI (29.64) sits more than 16 points above –DI (13.51), which places control firmly with buyers and represents a clear margin rather than a narrow tilt. ADX (29.52) adds the strength dimension. It climbed from a sub-20 trough in late September and pushed through the 25 threshold that separates trending from range-bound conditions. It then eased only modestly during the early-October consolidation and is now curling higher again. That pattern — a trend gauge that pauses without collapsing and then re-accelerates — points to a trend that is reasserting itself, not one that is fading. Just as telling is ADX’s position between the two DI lines, slightly beneath +DI. When ADX runs far above +DI and then rolls over, it often marks trend exhaustion. Here it is still building toward that line, which leaves room for the move to mature. Taken together with the triangle breakout, the structural and trend-strength reads point the same way.

#4 Bullish Aroon: The Aroon reading is as one-sided as the indicator gets: Aroon Up (orange) is pinned at 100% and Aroon Down (blue) sits at 0%. Aroon Up at 100% means yesterday printed the freshest high of the 14-session lookback, which confirms that the breakout carried price to new short-term highs rather than just back into the prior range. Aroon Down at 0% is equally informative. The lowest low in the window is a full 14 sessions old, so even yesterday’s gap-down open failed to print a new low before buyers took over. The brief early-October wobble, when Aroon Down rose toward 50% and Aroon Up slipped, has fully resolved in the bulls’ favor. The snap back to the extremes coincides with the triangle breakout, so the trend-timing signal is confirming the pattern rather than lagging it.

#5 Above Support Area with Downtrend Line Breakout: The weekly chart places the daily breakout in a larger structural context. The pink dotted level near $213.81 is a textbook role reversal. It capped multiple rebound attempts through 2025 before price reclaimed it, and it now sits directly beneath the current advance as support. That level also coincides with the multi-year downtrend line (pink dashed) that has run from the 2024 peak near $280 and governed every rally since. Price broke above that line in September. This week’s intraweek dip to $217.55 retested the broken trendline and was bought aggressively, leaving a long lower wick ahead of a $233.86 close. Price also holds above both the 50-week SMA ($205.37) and the 200-week SMA ($221.00), and the 200-week was reclaimed in September after acting as resistance for most of the past year. The honest nuance is that the 50-week still sits below the 200-week, so the long-term averages have not yet completed a golden cross. The 50-week is turning higher and the gap is narrowing, which makes an eventual weekly cross a logical next confirmation. Even before then, the multi-timeframe picture is clear: the daily triangle breakout is launching from a weekly floor where support, the broken trendline and the 200-week all converge. That alignment gives the setup more weight than either timeframe would carry alone.

DHR – Weekly Chart

#6 Bullish MACD: On the weekly chart, the MACD line (8.09) holds well above its signal line (4.74), with the histogram (3.35) firmly positive. The original crossover fired in June from deep negative territory near –10. That was an early signal and a noisy one, but it has since been fully validated, because both lines crossed above zero in August. That move shifted the longer-term momentum regime from bearish to bullish. A crossover above zero confirms an established trend rather than merely hinting at one. Recent behavior is the more interesting part. The histogram narrowed during the September consolidation, which reflected momentum digesting the prior run, and has now re-expanded as the MACD line steepens toward its late-2025 peak. A widening spread at this stage signals renewed acceleration. On a weekly basis it lines up with the daily ADX re-inflection in #3.

#7 Bullish Stochastic: The weekly stochastic shows %K (99.21) back above %D (93.20). This is a fresh crossover after a brief September dip, and it hands momentum back to buyers on a high-conviction timeframe. Both lines have stayed in the upper zone since July. That persistence — sometimes called an embedded stochastic — is itself a mark of trend strength, because each weekly bar keeps closing near the top of its recent range. The honest nuance is that both readings are deep in overbought territory, with %K close to the ceiling, so the move is stretched in the near term. Overbought conditions can persist for weeks in strong trends, so the reading is not a reason to stay away. It does mean a pullback offers a better-quality entry than chasing a vertical bar, which is the case for the $230 pullback level alongside the $237 breakout trigger.

Risks to Consider

Even strong setups can fail, especially in a large-cap life-sciences name like Danaher trading at a premium valuation. A few things could knock the stock off course:

• A breakdown back below the symmetrical triangle’s lower rail and 50-day SMA (around $215–$217) on heavy volume would invalidate the breakout thesis — and with the stock roughly 9% above its 50-day, a failure to clear the $237 January supply level could trigger a sharp pullback
• Negative company-specific news, broader market weakness, or regulatory changes in the healthcare and life-sciences sector could trigger a sell-off, and uneven end markets — academic and government budgets, China demand, and large-project timing — plus competition from larger peers like Thermo Fisher for biopharma and research budgets remain variables
• A soft Q4 growth outlook — the ~3% core-growth guide came in below the ~5% analysts expected, with respiratory testing expected to subtract about 1.5 percentage points (150 basis points) from growth
• Valuation leaves limited room for error — at $233.86, DHR trades at roughly 27.2x the midpoint of its FY2026 adjusted EPS guidance, and the $244.14 consensus target implies only about 4.4% upside
• Masimo integration and higher leverage — the roughly $9.9 billion cash acquisition was financed with cash and debt; Q3 interest expense nearly doubled to $135 million from $67 million, and Diagnostics core growth was just 0.5% despite 17% reported growth, making synergy delivery central to the thesis
• Earnings quality — Q3 GAAP earnings benefited from a $263 million discrete tax benefit, and tariff-refund effects also influenced the quarter, so headline GAAP results overstate the underlying run rate
• AI commercialization risk — the NVIDIA collaboration has no disclosed economics, and the autonomous lab’s up-to-8x speed and up-to-10x output figures are design targets; delays or weak customer adoption could limit valuation support
• Insider selling and leadership transition — then-CEO Rainer Blair sold 58,255 shares through a trust on August 21 for roughly $12.7 million, and his Form 4 filing did not mark the trades as part of a pre-arranged 10b5-1 plan; trackers also report no open-market insider purchases over the past year, while a brand-new CEO adds execution uncertainty

The Bottom Line

DHR is breaking out of a nine-month symmetrical triangle on the daily chart while holding above a key support area and a broken multi-year downtrend line on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: a Q3 earnings beat with raised full-year guidance, a new AI collaboration with NVIDIA, and $1.632 billion in quarterly free cash flow.

Combine that with multiple catalysts staggered through the coming months and into 2027 — the dividend payment on October 30, Q4 results and initial 2027 guidance in late January, Masimo synergy progress, the autonomous lab’s targeted scale-up in early 2027, and a new CEO setting her agenda — and DHR looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry options — a breakout entry and a pullback entry — both price targets that imply 14%–28% potential upside, and the stop-losses we’re using to manage the downside.

Recommended Trade Setup

We’re offering two ways to play this setup. Case 1 is a breakout entry above $237 — the level where sellers capped the stock in January — for traders who want confirmation before getting in. Case 2 is a pullback entry near $230, a retest of the triangle’s old upper rail, for traders who’d rather not chase a stock that’s already extended in the near term.

Case 1: On Breakout

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $19.00 per share, the target rewards are about $33.00 and $58.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If DHR drops to or below the $218.00 stop-loss before the $237.00 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Case 2: On Pullback

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $20.00 per share, the target rewards are about $40.00 and $65.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Happy Trading!
Tara and Greg